Results

Total Results: 723 records

Showing results for "diabetes treatment".
Users also searched for: diabetes guidelines

321. Executive Summary_Comparative Effectiveness Review No. 263: Management of Postpartum Hypertensive Disorders of Pregnancy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-263-postpartum-hypertensive-pregnancy-executive-summary.pdf
     May 01, 2023 - rising in the United States,1, 2 likely due to increased prevalence of pre-existing HTN, obesity, diabetes … KQ 2: What are the effectiveness, comparative effectiveness, and harms of pharmacological treatments … treatments for postpartum HTN. … Five RCTs compared oral antihypertensive treatments for persistent postpartum HTN. … ) Outcome Category Outcome HBPM in PP Individuals Pharmacological Treatments for HDP in PP Individuals

322. Intravascular Diagnostic Procedures and Imaging Techniques Versus Angiography Alone in Coronary Stenting: Future Research Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/coronary-artery-stenting-future_research.pdf
     January 01, 2014 - 4 3.78 7 What is the impact on clinical outcomes of a treatment decision (medical therapy, stent … 3 3.67 8 What is the impact on clinical outcomes of a treatment decision (medical therapy, stent … What is the impact on clinical outcomes of a treatment decision (medical therapy, stent, or bypass) … 4 4.00 7 What is the impact on clinical outcomes of a treatment decision (medical therapy, stent … 3 3.67 8 What is the impact on clinical outcomes of a treatment decision (medical therapy, stent

323. Psoriasis-Chronic Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/psoriasis-chronic_executive.pdf
     November 01, 2012 - modalities when making therapeutic decisions. … outcomes (mortality, HRQoL [e.g., DLQI, HAQ-DI, EQ-5D] and other patient-reported outcomes, MACE, diabetes … within the biologic, nonbiologic, and phototherapy treatments. … There was insufficient evidence to evaluate myocardial infarction and diabetes mellitus, and no other … Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities.

324. Progestogens-Preterm-Birth Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/progestogens-preterm-birth_executive.pdf
     September 01, 2012 - Effectiveness Reviews, the program supports systematic appraisals of existing scientific evidence regarding treatments … limited to: • Complications during pregnancy (e.g. allergic reactions or development of gestational diabetes … frequency of administration, and gestational age at initiation or discontinuation of progestogen therapy … Modifiers of Outcomes by Cointerventions Ten studies with distinct populations reported using tocolytic treatments … Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled

325. Strategies for Patient, Family and Caregiver Engagement: Technical Brief Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/patient-family-engagement-protocol.pdf
     December 31, 2019 - self-management o Self-management programs o Shared decision making (e.g., palliative or end of life or treatment … Diabetes Res Clin Pract. 2013 May;100(2):145-61. doi: 10.1016/j.diabres.2012.12.016. … National standards for diabetes self-management education. … Diabetes Care. 2012 Jan;35 Suppl 1:S101-8. doi: 10.2337/dc12-s101. PMID: 22187467. 8. … Managing depression as a chronic disease: a randomised trial of ongoing treatment in primary care.

326. Politi (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/politi.pdf
     October 08, 2025 - Sensitive Decisions: • BCS vs. mastectomy for average risk patients with early stage breast cancer • Diabetes … Conversational Recommendations (3) • Discuss how to determine whether there is any benefit  from treatment

327. Cer-250-Cannabis-2025-Surv-Rep-Update-Table-E5 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2025-surv-rep-update-table-e5.xlsx
     January 01, 2025 - Duration Measure (Mean, Median) Pain Duration, Months Psychiatric Comorbidity % N Interventions Dose Treatment … B Median reported change in NRS scores across treatment sessions: -3.0 (IQR -4.5 to -2.0) NR NR NR NR … Long NR Ischemic heart disease, hypertension, heart failure, chronic obstructive pulmonary disease, diabetes … agent, cancer as underlying pain diagnosis, and history of cardiometabolic disease (e.g., hypertension, diabetes … B: Long-acting opioid analgesics as an add-on treatment Mean (SD) A: 6.2 (2.4) sprays/day (16.74 mg

328. Disposition of Comments for Screening for Glaucoma: Comparative Effectiveness (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/glaucoma-screening_disposition-comments.pdf
     April 01, 2012 - Glauocma Medical Diagnosis and Therapy Volume One. Saunders. 2009 pp. 15-23. … As Pfizer’s efforts in this therapeutic area continue, we look forward to further collaboration with … the Agency on improving the body of clinical evidence for glaucoma and other important therapeutic … Glaucoma Medical Diagnosis and Therapy Volume One. Saunders. 2009 pp. 15-23. 2. … The report on treatment shows that there are effective treatments, so screening should be an aim of

329. CER 218 Disposition of Comments: Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-218-osteoporosis-disposition-comments.pdf
     April 23, 2019 - Since there are no FDA approved treatments within the anti-sclerostin monoclonal antibody class, Amgen … vertebral fracture.2,4,6 Therefore, w hile drug holidays may be an option for certain osteoporosis therapies … Lancet Diabetes Endocrinol 2017;5:513-523. … While drug holidays may be an option for certain therapies, DMB should not be discontinued without … Given that there are no other treatments within the anti-sclerostin monoclonal antibody class, this

330. Slide 1
     effectivehealthcare.ahrq.gov/sites/default/files/sensitivity-analysis-chapter-11.pptx
     January 01, 2013 - For example, when studying the association between thiazide diuretics and diabetes, one would presume … that the risk of incident diabetes among the “distant past users” should resemble that of the “nonusers … Therapies are often tested on an ideal population. … Important subpopulations include: - Pediatric populations: Children may respond differently to therapy … Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics

331. Project Name: (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/sleep-apnea_disposition-comments.pdf
     October 25, 2011 - The search criteria covered combination therapies. … using the various therapies are to be fully understood. … of patients, based on: race, gender, body mass index (BMI), existing non- insulin dependent diabetes … of patients, based on: race, gender, body mass index (BMI), existing non- insulin dependent diabetes … Furthermore, surgical treatment is often used in cases of failure of CPAP therapy and in those patients

332. PHARMACO-EPIDEMIOLOGIC METHODS FOR A STUDY OF (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/antipsychotic-medicine-mortality-elderly_research.pdf
     March 01, 2009 - Clinical conditions were defined as having both diagnosis for a condition and treatment indicating … These comorbidities include arrhythmias, diabetes, cerebrovascular disease (e.g., both cerebral hemorrhagic … Report Number 11 6 Discussion In this study of over 30,000 elderly patients initiating APM treatments … Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? … therapy 1.11 (0.89-1.38) 1.06 (0.79-1.41) 80-180 days after beginning therapy 1.20 (1.03-1.41) 1.25

333. Long-Term Drug Therapy and Drug Holidays for Osteoporotic Fracture Prevention (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/research-protocol-osteoporosis_2.pdf
     October 05, 2018 - Long-Term Drug Therapy and Drug Holidays for Osteoporotic Fracture Prevention 1 Evidence-based … drug treatment to maximize therapeutic benefit (e.g., reduced fracture risk) while minimizing harms … estrogen-related treatments), race, sex, comorbid conditions (DM, CKD, CVD), osteoporosis status … intervals CKD chronic kidney disease CTX C-terminal telopeptide CVD cardiovascular disease DM diabetes … Date Section Original Protocol Revised Protocol Rationale 10/5/18 Title Appropriate Use of Drug Therapies

334. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/disparities-quality-improvement_research-protocol.pdf
     February 23, 2012 - interdisciplinary process to raise the likelihood of the delivery of best practices for preventive, diagnostic, therapeutic … Individuals in the United States with a priority condition (i.e. breast cancer, colorectal cancer, diabetes … Unequal treatment : confronting racial and ethnic disparities in health care. … Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare. … Footnote one states: Priority conditions include: colorectal cancer screening; diabetes; congestive

335. Evidence Summary: Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-221-copd-evidence-summary_0.pdf
     October 01, 2019 - from systemic corticosteroids, in particular hyperglycemia, in patients with glucose intolerance and diabetes … on evidence from randomized controlled trials (RCTs) as the gold standard design for evaluating a therapeutic … and individual treatments. … The response to antibiotic therapy as well as corticosteroid therapy in ECOPD likely differs based … therapy versus placebo in ECOPD,48 but identification of responders to systemic corticosteroid treatment

336. Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease: Future Research Needs (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/chronic-kidney-disease-anemia_research.pdf
     January 01, 2013 - regimen (i.e., repletion or continuous treatment) o Interactions between treatments (i.e., patients … regimen (i.e., repletion or continuous treatment) • Interactions between treatments (i.e., patients … regimen (i.e., repletion or continuous treatment) o Interactions between treatments (i.e., patients … 10 Abbreviations: CMS = Center for Medicare and Medicaid Services; NIDDK = National Institute of Diabetes … and clinical utility of iron status vary according to patients with different comorbidities (e.g., diabetes

337. Gout Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/gout_executive.pdf
     March 01, 2016 - Diabetes and gout: efficacy and safety of febuxostat and allopurinol. … Diabetes Obes Metab. 2013 Nov;15(11):1049-55. PMID: 23683134. 63. … The dynamics of chronic gout treatment: medication gaps and return to therapy. … Adherence with urate-lowering therapies for the treatment of gout. … between gout flares, time in treatment, serum uric acid level and urate lowering therapy.

338. Disposition of Comments for Technical Brief 28 MAT Models (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/opioid-use-disorder_disposition-comments.pdf
     December 06, 2016 - Lifestyle modification is an important part of the treatment of lipid disorders, diabetes and hypertension … We don't refer to treatments for other chronic diseases as Medication Assisted Treatment. … When we treat diabetes we don't speak of "medication-assisted dietary therapy" -- we say they are on … We would never call medication treatment of hypertension or diabetes "medication- assisted" treatment … counseling and other non-pharmacologic therapies."

339. Renal-Function Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/renal-function_research-protocol.pdf
     June 13, 2013 - characteristic ST elevation myocardial infarction (STEMI) can be evaluated for emergent reperfusion therapy … For example, therapy for type II MIs is most often directed at treating the underlying medical condition … Comorbidities (e.g., diabetes, hypertension) i. … Comorbidities (e.g., diabetes, hypertension) i. … Comorbidities (e.g., diabetes, hypertension) i.

340. Chronic-urinary-retention-protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/chronic-urinary-retention_research-protocol.pdf
     November 19, 2012 - Examples of neurologic causes include spinal cord injury (SCI), stroke, multiple sclerosis (MS), and diabetes … Testing and Treatment Treatment for CUR is dependent on etiology. … , and pharmacologic treatments. … Table 1 lists the various surgical and nonsurgical treatments for CUR. … silodosin); 5-Alpha Reductase Inhibitors (5-ARI): dutasteride, finasteride; AB + 5- ARI combination therapy